Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil; Antonio D’Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Y. Wu; Celina Ang; Thomas U. Marron; Arndt Weinmann; Peter R. Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei‐Chang Lee; Yi‐Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J. Pinato; Rohini Sharma

doi:10.1111/liv.15405

Related publications

Dataset

Supplementary Material for: Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable Hepatocellular Carcinoma: Results From Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

Li D, Toh H.C., Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, A. Nicholas, Masatoshi Kudo

Article2023

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, M. Lorraine Leibfried, Catherine Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo

Article2023

Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada,

Article2025

Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study

Atsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, ,

Article2023

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Margherita Rimini, Andrea Casadei‐Gardini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Mario Scartozzi, Valentina Burgio, Stefano Cascinu, Alessandro Cucchetti

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Abstract

Discussion(0)

Related publications

Supplementary Material for: Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable Hepatocellular Carcinoma: Results From Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study

Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.